Title : Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo.

Pub. Date : 2019

PMID : 31019975






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo. Fluorouracil erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 Western blot analysis showed that gemcitabine/5-fluorouracil increased the expressions of total and phosphorylated forms of HER2, thus enhancing the cytotoxicity of trastuzumab. Fluorouracil erb-b2 receptor tyrosine kinase 2 Homo sapiens
3 Our in vivo and in vitro data suggest that sequential therapy with gemcitabine/5-fluorouracil followed by trastuzumab represents a novel and promising therapeutic strategy against HER2-negative GBC. Fluorouracil erb-b2 receptor tyrosine kinase 2 Homo sapiens
4 The upregulation of phosphorylated HER2 and phosphorylated-AKT induced by gemcitabine/5-fluorouracil treatment shows that HER2/AKT pathway is triggered. Fluorouracil erb-b2 receptor tyrosine kinase 2 Homo sapiens
5 The upregulation of phosphorylated HER2 and phosphorylated-AKT induced by gemcitabine/5-fluorouracil treatment shows that HER2/AKT pathway is triggered. Fluorouracil erb-b2 receptor tyrosine kinase 2 Homo sapiens